A new collaboration agreement has been signed between the Swedish company NeuroVive Pharmaceutical and Karolinska Institutet in order to develop NeuroVive’s cyclophilin inhibitor compound NV556 for the treatment of mitochondrial myopathy, an area of high unmet medical need. The new compound is expected to have higher specificity and tolerability than ciclosporin, which may facilitate better optimization of dosage. The collaboration will allow NeuroVive to reinforce its presence in the genetic mitochondrial disease key focus area where the company is also developing NVP015 compounds in mitochondrial respiratory chain diseases.